Lori J. Pease

2.3k total citations · 1 hit paper
26 papers, 1.5k citations indexed

About

Lori J. Pease is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Lori J. Pease has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Lori J. Pease's work include Histone Deacetylase Inhibitors Research (7 papers), Protein Degradation and Inhibitors (6 papers) and HER2/EGFR in Cancer Research (5 papers). Lori J. Pease is often cited by papers focused on Histone Deacetylase Inhibitors Research (7 papers), Protein Degradation and Inhibitors (6 papers) and HER2/EGFR in Cancer Research (5 papers). Lori J. Pease collaborates with scholars based in United States, United Kingdom and Denmark. Lori J. Pease's co-authors include Dale E. McCall, Andrew T. Chiu, William F. Herblin, Pancras C. Wong, Ruth R. Wexler, Robert Ardecky, David J. Carini, A.L. Johnson, John V. Duncia and Pieter B.M.W.M. Timmermans and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Lori J. Pease

25 papers receiving 1.5k citations

Hit Papers

Identification of angiotensin II receptor subtypes 1989 2026 2001 2013 1989 200 400 600

Peers

Lori J. Pease
Robert L. Panek United States
Angelo J. Trapani United States
Nathan B. Mantlo United States
Gillian M. Olins United States
Indira Sen United States
Dilip Amin United States
Jeffrey A. Stafford United States
Thomas A. Morinelli United States
Kenneth J. Shaw United States
Robert L. Panek United States
Lori J. Pease
Citations per year, relative to Lori J. Pease Lori J. Pease (= 1×) peers Robert L. Panek

Countries citing papers authored by Lori J. Pease

Since Specialization
Citations

This map shows the geographic impact of Lori J. Pease's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori J. Pease with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori J. Pease more than expected).

Fields of papers citing papers by Lori J. Pease

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori J. Pease. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori J. Pease. The network helps show where Lori J. Pease may publish in the future.

Co-authorship network of co-authors of Lori J. Pease

This figure shows the co-authorship network connecting the top 25 collaborators of Lori J. Pease. A scholar is included among the top collaborators of Lori J. Pease based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori J. Pease. Lori J. Pease is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pease, Lori J., et al.. (2024). Systematic transcriptomic analysis and temporal modelling of human fibroblast senescence. SHILAP Revista de lepidopterología. 5. 1448543–1448543. 3 indexed citations
2.
Curtin, Michael L., Robin R. Frey, H. Robin Heyman, et al.. (2012). Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. Bioorganic & Medicinal Chemistry Letters. 22(9). 3208–3212. 19 indexed citations
3.
Dai, Yujia, Niru B. Soni, Lori J. Pease, et al.. (2007). Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(1). 386–390. 31 indexed citations
4.
Heyman, H. Robin, Robin R. Frey, Peter F. Bousquet, et al.. (2006). Thienopyridine urea inhibitors of KDR kinase. Bioorganic & Medicinal Chemistry Letters. 17(5). 1246–1249. 33 indexed citations
5.
Li, Junling, Lori J. Pease, Paul Tapang, et al.. (2005). ABT-869 a novel multi-targeted receptor tyrosine kinase inhibitor: characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia. Cancer Research. 65. 1407–1407.
6.
Glaser, Keith B., Lori J. Pease, Michael J. Staver, et al.. (2004). Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochemical and Biophysical Research Communications. 325(3). 683–690. 51 indexed citations
7.
Curtin, Michael L., Robin R. Frey, H. Robin Heyman, et al.. (2004). Isoindolinone ureas: a novel class of KDR kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(17). 4505–4509. 26 indexed citations
8.
Dai, Yujia, Yan Guo, Jun Guo, et al.. (2003). Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. Bioorganic & Medicinal Chemistry Letters. 13(11). 1897–1901. 34 indexed citations
9.
Vasudevan, Anil, Zhiqin Ji, Robin R. Frey, et al.. (2003). Heterocyclic ketones as inhibitors of histone deacetylase. Bioorganic & Medicinal Chemistry Letters. 13(22). 3909–3913. 33 indexed citations
10.
Wada, Carol K., Robin R. Frey, Zhiqin Ji, et al.. (2003). α-Keto amides as inhibitors of histone deacetylase. Bioorganic & Medicinal Chemistry Letters. 13(19). 3331–3335. 67 indexed citations
11.
Dai, Yujia, Yan Guo, Michael L. Curtin, et al.. (2003). A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorganic & Medicinal Chemistry Letters. 13(21). 3817–3820. 33 indexed citations
12.
Curtin, Michael L., Robert B. Garland, H. Robin Heyman, et al.. (2002). Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC). Bioorganic & Medicinal Chemistry Letters. 12(20). 2919–2923. 97 indexed citations
13.
Frey, Robin R., Carol K. Wada, Robert B. Garland, et al.. (2002). Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorganic & Medicinal Chemistry Letters. 12(23). 3443–3447. 116 indexed citations
14.
Holms, James H., Patrick A. Marcotte, Junling Li, et al.. (2001). Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme. Bioorganic & Medicinal Chemistry Letters. 11(22). 2907–2910. 41 indexed citations
15.
Glaser, Keith B., Lori J. Pease, Junling Li, & Douglas W. Morgan. (1999). Enhancement of the surface expression of tumor necrosis factor α (TNFα) but not the p55 TNFα receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors. Biochemical Pharmacology. 57(3). 291–302. 20 indexed citations
16.
Glaser, Keith B., Robert P. Metzger, Thoru Pederson, et al.. (1997). Expression, release, and regulation of human TNFα from stable transfectants of HEK-293 cells. Inflammation Research. 46(0). 127–128. 3 indexed citations
17.
Mousa, Shaker A., et al.. (1994). Role of platelet GPIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release. Life Sciences. 54(16). 1155–1162. 8 indexed citations
18.
Chiu, Andrew T., Shaker A. Mousa, Lori J. Pease, et al.. (1991). Inhibition of the thrombin-platelet reactions by DuP 714. Biochemical and Biophysical Research Communications. 179(3). 1500–1508. 4 indexed citations
19.
Herblin, William F., Andrew T. Chiu, Dale E. McCall, et al.. (1991). Angiotensin II Receptor Heterogeneity. American Journal of Hypertension. 4(4_Pt_2). 299S–302S. 50 indexed citations
20.
Chiu, Andrew T., William F. Herblin, Dale E. McCall, et al.. (1989). Identification of angiotensin II receptor subtypes. Biochemical and Biophysical Research Communications. 165(1). 196–203. 705 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026